For investors in healthcare stocks, 1995 was a much-needed shotin the arm that remedied a three-year period of falling shareprices. An annual survey by WDI Capital Markets of Hilton Head,SC, saw a strong surge in share prices among healthcare
For investors in healthcare stocks, 1995 was a much-needed shotin the arm that remedied a three-year period of falling shareprices. An annual survey by WDI Capital Markets of Hilton Head,SC, saw a strong surge in share prices among healthcare companieslast year. Vendors of cardiac instruments led the charge in stockvaluation growth, although manufacturers of medical imaging devicesturned in a strong performance as well.
For the year, overall healthcare industry share prices leaped40.1%, compared with a 4.7% decline in 1994. Share prices dropped9.4% in 1993 and 10.6% in 1992.
Among public imaging device companies, stock prices trackedby WDI climbed 75.8% in 1995, compared with a lackluster gainof 1.2% in 1994. ThermoTrex led the segment with share-price growthof 270%, while bone densitometry firm Hologic jumped 173%. Othervendors turning in strong performances for the year were bonedensitometry vendor Lunar, up 129%; image-guided catheter manufacturerEndosonics, up 122%; x-ray vendor Fischer Imaging, up 85%; andnuclear medicine firm ADAC Laboratories, up 55%.
Imaging services firms also enjoyed rising stock valuations,according to WDI's survey. Share prices in the segment rose anaverage of 52.2% for the year.
In other WDI news, the investment and advisory firm announcedthat former Fischer Imaging executive Robert Cascella has joinedthe company as president.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.